- Colchicine did not succeed in relieving symptoms and inflammation of knee osteoarthritis (KOA) in a 16-week Colchicine effectiveness in symptoms and inflammation modification in knee osteoarthritis (COLKOA) trial.
Why this matters
- Since the trial showed some improvement in inflammation, its 16-week duration may not have been long enough to succeed.
- This was a double-blind, placebo-controlled randomized trial of 0.5 mg twice-daily oral colchicine vs placebo in KOA.
- The primary outcome was ≥30% improvement in total Western Ontario and McMaster Universities Osteoarthritis Index at week 16.
- Funding: Duke Collaborative Research Grant; Centre Grants of Singapore General Hospital; National Medical Research Council, Singapore.
- Odds of achieving primary response was similar with colchicine vs placebo (38.9% vs 49.1%; P=.284), corresponding to an adjusted OR of 0.58 (P=.184).
- In the colchicine group, there were nonsignificant reductions in synovial fluid levels of IL-6, IL-8, TNFα, CD14, and IL-18, and lower mean serum high-sensitivity C-reactive protein (P=.008) and synovial fluid C-terminal crosslinked telopeptide of type I collagen (P=.002).
- Small sample size.
- Lower than expected effect size in the treatment arm.